Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537875 | 0.92 | ALDH1A1 (0.37) | ALDH1A1KDM4EHPGDHSD17B10TDP1 | |
| SCHEMBL3538082 | 0.92 | SHMT2 (0.43) | ALDH1A1HPGDTDP1HTR2CGAA | |
| SCHEMBL3542155 | 0.90 | PIM1 (0.42) | ALDH1A1KDM4EHPGDHSD17B10HTR2C | |
| SCHEMBL3545648 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDHSD17B10TDP1 | |
| SCHEMBL3540890 | 0.86 | HTR2C (0.41) | HTR2CSCN9AKCNH2 | |
| SCHEMBL3540062 | 0.86 | PIM1 (0.40) | PDE2A | |
| SCHEMBL3544618 | 0.85 | CCNT1 (0.40) | ALDH1A1PDE2A | |
| SCHEMBL3545577 | 0.84 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10SCD5 | |
| SCHEMBL3536850 | 0.83 | HTR2C (0.39) | HTR2CSHMT2 | |
| SCHEMBL3538068 | 0.83 | CPT1A (0.41) | ALDH1A1KDM4EHPGDHTR2CSHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101370796-A | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | claimed |
| CN-101370796-B | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE | 2012-10-10 | — | — | CN | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| CN-101370796-A | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | ALDH1A1 707/4885KDM4E 1513/4885HPGD 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.